Researchers have made significant progress in the treatment of a rare type of hearing loss linked to genetic mutations. Regeneron Pharmaceuticals has announced that the European Medicines Agency has accepted their gene therapy, Otarmeni, for review. This therapy targets biallelic OTOF variant-associated hearing loss, which affects about 46 newborns each year in the EU. If approved, Otarmeni will be the first gene therapy available for this condition in Europe, offering hope for restoring hearing in affected individuals.

For people facing this specific type of hearing loss, Otarmeni could represent a breakthrough. Currently, those with OTOF-related hearing loss rely on hearing aids, which can amplify sound but do not restore full hearing capabilities. The therapy aims to deliver a functional copy of the OTOF gene directly to the inner ear, potentially allowing patients to regain normal hearing. The pivotal CHORD clinical trial showed promising results, with 24 participants aged 10 months to 16 years receiving the therapy, indicating a significant step toward improving quality of life for these children and adolescents.

While the results from the CHORD trial are encouraging, the research is still in the early stages. The trial is ongoing and is currently enrolling more participants across multiple countries, including the U.S., U.K., Spain, Germany, and Japan. Although Otarmeni has received accelerated approval in the U.S., its safety and efficacy have yet to be fully evaluated outside the U.S. Therefore, while the potential for restoring hearing is exciting, further evidence is needed to confirm its effectiveness and safety in broader populations.

Source: globenewswire.com